<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92192</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Issledovanie ASCOT kak argument v bor'be "novogo" so "starym" i shag k pereotsenke "sistemy tsennostey"</article-title><trans-title-group xml:lang="ru"><trans-title>Исследование ASCOT как аргумент в борьбе "нового" со "старым" и шаг к переоценке "системы ценностей"</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Boytsov</surname><given-names>S. A</given-names></name><name xml:lang="ru"><surname>Бойцов</surname><given-names>С. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Российский кардиологический научно-производственный комплекс, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2006-11-15" publication-format="electronic"><day>15</day><month>11</month><year>2006</year></pub-date><volume>8</volume><issue>11</issue><issue-title xml:lang="en">VOL 8, NO11 (2006)</issue-title><issue-title xml:lang="ru">ТОМ 8, №11 (2006)</issue-title><fpage>5</fpage><lpage>11</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2006, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2006, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2006</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/92192">https://consilium.orscience.ru/2075-1753/article/view/92192</self-uri><abstract xml:lang="ru"><p>Исследование ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) триумфально финишировало в 2005 г., доказав, что комбинация "новых" антигипертензивных средств - антагонистов кальция и ингибиторов ангиотензинпревращающего фермента (ИАПФ) лучше, чем комбинация "старых" - b-адреноблокаторов и диуретиков.</p></abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>антигипертензивные препараты</kwd><kwd>сердечно-сосудистый риск</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Culter J, Mac Mahon S, Furberg C. Controlled clinical trials of drug treatment for hypertension: a review. Hypertension 1989; 13: 136-44.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Poulter N, Sever P. Anglo-Scandinavian Cardiac Outcomes Trial. History, results and implications for the management of high blood pressure. Birmingham: Sherborne Gibbs Ltd 2005.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Neal B. Blood Pressure-Lowering Treatment Trialists Collaboration. Lancet 2000; 356: 1956-64.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Blood Pressure-Lowering Treatment Trialists Collaboration. Effects of different blood - pressure - lowering regimens on major cardiovascular events: results of prospectively - designed overviews of randomized trials. Lancet 2003; 362: 1527-45.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Weber M.A. The ALLHAT Report: A case of Information and Misinformation. J Clin Hypertens 2003; 5 (1): 9-13.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Moser M. Results of the ALLHAT Trial: Is the Debate About Initial Antihypertensive Drug Therapy Over? J Clin Hypertens 2003; 5 (1): 5-8.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Schmieder R.E, Schlaich M.P, Klingbeli A.U et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta - analysis of all randomaized double - blind studies until December 1996). Nephrol Dial Transplant 1998; 13: 554-69.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kjeldsen S.E, Dahlof B, Devereux R.B et al. Losartan Intervention for Endpoint Reduction (LIFE) Study Group: Effect of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: Losartan Intervention for Endpoint Reduction (LIFE) substudy. J Am Med Assoc 2002; 288: 1491-8.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Nichols W.W, O'Rourke M.F. Mc Donald's blood flow in arteries: theoretic, experimental and clinical principles. 5th ed. Edward Arnold, London, 2005.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Brown D.W, Giles W.H, Croft J.B. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000; 140 (6): 848-56.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>London G.M, Asmar R.G, O,Rourke M.F, Safar M.E. REASON Project Investigators: Mechanism(s) of selective systolic blood pressure reduction after a low dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43: 92-9.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Lonn E, Shaikholeslami R, Yi Q, Bosch J et al. Effect of ramipril on left ventricular mass and function in cardiovascular patients wih controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol 2004; 43: 2200-6.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Mahmud A, Feely J. Arterial Stiffness and Antihypertensive Therapy. Expert Rev Cardiov Ther 2003; 1: 65-72.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Tropeano A-I, Boutouyrie P, Pannier B et al. Brachial pressure - independent reduction in carotid stiffnes after long - term angiotensin - convertinge enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48 (1): 80-6.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Nichols W.W. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertension 2005; 18 (1, Part 2): 3S-10S.</mixed-citation></ref></ref-list></back></article>
